The linkage of allergic rhinitis and obstructive sleep apnea

 

Vol. 32, No. 4, December 2014 > Chirakalwasan

The linkage of allergic rhinitis and obstructive sleep apnea

Naricha Chirakalwasan, Kiat Ruxrungtham

Abstract

Rhinitis can be divided into allergic and non-allergic rhinitis. Rhinitis, particularly allergic rhinitis, has been shown to be associated with obstructive sleep apnea; a condition characterized by repetitive upper airway obstruction during sleep.

Impact of a countywide smoke-free workplace law on emergency department visits for respiratory diseases: a retrospective cohort study

Research article

Ivana T Croghan, Jon O Ebbert, James T Hays, Darrell R Schroeder, Alanna M Chamberlain,Véronique L Roger and Richard D Hurt

BMC Pulmonary Medicine 2015, 15:6  doi:10.1186/1471-2466-15-6

Published: 22 January 2015

Abstract (provisional)

Background

With the goal of reducing exposure to secondhand smoke, the state of Minnesota (MN), enacted a smoke-free law (i.e., Freedom to Breathe Act) in all workplaces, restaurants, and bars in 2007. This retrospective cohort study analyzes emergency department (ED) visits in Olmsted County, MN, for chronic obstructive pulmonary disease (COPD) and asthma over a five-year period to assess changes after enactment of the smoke-free law.

Successful Desensitization of a Patient with Rituximab Hypersensitivity

Case Reports in Immunology
Volume 2015 (2015), Article ID 524507, 4 pages
http://dx.doi.org/10.1155/2015/524507

Case Report

Pinar Ataca,1 Erden Atilla,1 Resat Kendir,2 Sevim Bavbek,2 and Muhit Ozcan1

1Department of Hematology, Ankara University, Cebeci, 06590 Ankara, Turkey
2Department of Pulmonary Medicine, Immunology and Allergy Clinic, Ankara University, Cebeci, 06590 Ankara, Turkey

Received 8 November 2014; Revised 1 January 2015; Accepted 1 January 2015

Academic Editor: Ahmad M. Mansour

Copyright © 2015 Pinar Ataca et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization. In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered.

Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany

Research

Bram G Verheggen^1*, Kirsten Y Westerhout¹, Carl H Schreder² and Matthias Augustin³

Clinical and Translational Allergy 2015, 5:1  doi:10.1186/s13601-015-0045-z

Published: 21 January 2015

Abstract (provisional)

Background

Allergoids are chemically modified allergen extracts administered to reduce allergenicity and to maintain immunogenicity. Oralair (the 5-grass tablet) is a sublingual native grass allergen tablet for pre- and co-seasonal treatment. Based on a literature review, meta-analysis, and cost-effectiveness analysis the relative effects and costs of the 5-grass tablet versus a mix of subcutaneous allergoid compounds for grass pollen allergic rhinoconjunctivitis were assessed.

Efficacy of Add-on Montelukast in Nonasthmatic Eosinophilic Bronchitis: The Additive Effect on Airway Inflammation, Cough and Life Quality

ORIGINAL ARTICLE

Year : 2015  |  Volume : 128  |  Issue : 1  |  Page : 39-45

Wuping Bao¹, Ping Liu², Zhongmin Qiu³, Li Yu³, Jingqing Hang⁴, Xiaohua Gao⁴, Xin Zhou^1
1 Department of Respiratory Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China
² Department of Respiratory Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080; Department of Respiratory Medicine, Tongji Hospital, Tongji University, School of Medicine, Shanghai 200065, China
³ Department of Respiratory Medicine, Tongji Hospital, Tongji University, School of Medicine, Shanghai 200065, China
⁴ Department of Respiratory Medicine, Shanghai Putuo People's Hospital, Shanghai 200060, China

Date of Submission	28-Oct-2014
Date of Web Publication	26-Dec-2014

DOI: 10.4103/0366-6999.147805

PMID: 25563311

Abstract

Background: The efficacy of montelukast (MONT), a cysteinyl leukotriene receptor antagonist, in nonasthmatic eosinophilic bronchitis (NAEB), especially its influence on cough associated life quality is still indefinite. We evaluated the efficacy of MONT combined with budesonide (BUD) as compared to BUD monotherapy in improving life quality, suppressing airway eosinophilia and cough remission in NAEB.
Methods: A prospective, open-labeled, multicenter, randomized controlled trial was conducted. Patients with NAEB (aged 18-75 years) were randomized to inhaled BUD (200 μg, bid) or BUD plus oral MONT (10 μg, qn) for 4 weeks. Leicester cough questionnaire (LCQ) life quality scores, cough visual analog scale (CVAS) scores, eosinophil differential ratio (Eos), and eosinophil cationic protein (ECP) in induced sputum were monitored and compared.
Results: The control and MONT groups contained 33 and 32 patients, respectively, with similar baseline characteristics. Significant with-in group improvement in CVAS, LCQ scores, Eos, and ECP was observed in both groups during treatment. After 2-week treatment, add-on treatment of MONT was significantly more effective than BUD monotherapy for CVAS decrease and LCQ scores improvement (both P - 0.05). Similar results were seen at 4-week assessment (both P - 0.05). 4-week add-on therapy of MONT also resulted in a higher percentage of patients with normal sputum Eos (-2.5%) and greater decrease of ECP (both P - 0.05).
Conclusions: MONT combined with BUD was demonstrated cooperative effects in improvement of life quality, suppression of eosinophilic inflammation, and cough remission in patients with NAEB.

Keywords: Budesonide; Cough; Quality of Life; Montelukast; Bronchitis

How to cite this article: Bao W, Liu P, Qiu Z, Yu L, Hang J, Gao X, Zhou X. Efficacy of Add-on Montelukast in Nonasthmatic Eosinophilic Bronchitis: The Additive Effect on Airway Inflammation, Cough and Life Quality. Chin Med J 2015;128:39-45

How to cite this URL: Bao W, Liu P, Qiu Z, Yu L, Hang J, Gao X, Zhou X. Efficacy of Add-on Montelukast in Nonasthmatic Eosinophilic Bronchitis: The Additive Effect on Airway Inflammation, Cough and Life Quality. Chin Med J [serial online] 2015 [cited 2015 Jan 24];128:39-45. Available from: http://www.cmj.org/text.asp?2015/128/1/39/147805

Delayed Anaphylaxis to Red Meat Associated With Specific IgE Antibodies to Galactose

Abstract
	Case Report  Open Access
	Allergy Asthma Immunol Res. 2015 Jan;7(1):92-94. English. Published online Jun 09, 2014.  http://dx.doi.org/10.4168/aair.2015.7.1.92  Copyright © 2015 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease Liping Wen,1, Junxiong Zhou,1, Jia Yin,1 Jin-lu Sun,1 Yi Sun,2 Kai Wu,1 and Rohit Katial3 1Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. 2State Key Laboratory Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China. 3Department of Allergy and Immunology, National Jewish Medical and Research Center, University of Colorado, Denver, CO, USA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract A novel delayed anaphylactic reaction to red meat, associated with tick bites and IgE antibodies against galactose-α-1, 3-galactose (α-gal), was reported in 2009 in the US, Australia and Europe. In this case, serum specific IgE to galactose-α-1, 3-galactose (>100 kU/L) and IgE to multiple non-primate mammalian proteins were positive. However, the pathogenesis of this disease remains unclear. We report the first case in Asia of delayed anaphylactic reaction to red meat, which was induced by bites from the hard tick, Hematophagous ixodidae. We confirmed the increased concentration of IgE reactive epitopes in non-primate mammalian organs, which may be rich in α-gal proteins in lymphatic and endothelial tissues. All confirmed ticks associated with this disorder in the literature and in our case belonged to the hard tick family. We hypothesize that hard tick saliva is enriched with blood-type substances, such as oligosaccharides, from the non-primate mammal victim's blood after days to weeks of blood sucking, which sensitizes humans through the injection route while blood sucking. Keywords: Food allergy, anaphylaxis, red meat allergy, tick. Case Report  Open Access

A retrospective study of the clinical benefit from acetylsalicylic acid desensitization in patients with nasal polyposis and asthma

Research

Christine Ibrahim^1*, Kulraj Singh¹, Gina Tsai¹², David Huang¹², Jorge Mazza¹², Brian Rotenberg¹³, Harold Kim¹² and David William Moote^12*

Allergy, Asthma & Clinical Immunology 2014, 10:64  doi:10.1186/s13223-014-0064-7

Published: 11 December 2014

Quality of life in relation to the traffic pollution indicators NO2 and NOx: results from the Swedish GA2LEN survey

BMJ Open Resp Res 2014;1:e000039 doi:10.1136/bmjresp-2014-000039

1. Johan Nilsson Sommar1, 
2. Alexandra Ek2, 
3. Roelinde Middelveld3,4, 
4. Anders Bjerg5,
5. Sven-Erik Dahlén2, 
6. Christer Janson6 and 
7. Bertil Forsberg1

+Author Affiliations

1. ¹Occupational and Environmental Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
2. ²Experimental Asthma and Allergy Research Unit, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
3. ³The Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
4. ⁴The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
5. ⁵Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, Krefting Research Centre, University of Gothenburg, Göteborg, Sweden
6. ⁶Department of Medical Sciences: Respiratory Medicine and Allergology, Uppsala University, Uppsala, Sweden

1. Correspondence toDr Johan Nilsson Sommar; johan.n.sommar@envmed.umu.se